Tags

Type your tag names separated by a space and hit enter

Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
Cutis. 1999 Jan; 63(1):41-8.C

Abstract

A photographic tracking study was performed to facilitate a visual evaluation of the effect of treating psoriatic lesions in a clinical setting with tazarotene 0.05% gel, tazarotene 0.1% gel, tazarotene 0.1% gel plus mometasone furoate as needed for irritation, or tazarotene 0.1% gel plus mometasone furoate. Tazarotene was administered once daily in the evening, and mometasone furoate was administered once daily in the morning, for 12 weeks or until clearance if this occurred first. A total of twenty patients were enrolled in this open-label study. Rates of treatment success (50% or greater improvement in psoriasis) were higher with tazarotene 0.1% monotherapy compared with tazarotene 0.05% monotherapy, and were higher still when tazarotene was used in combination with mometasone furoate. Concurrent use of this steroid also enhanced speed of efficacy, patient satisfaction, and tolerability. Furthermore, long periods of remission were achieved in patients treated with combination tazarotene plus corticosteroid therapy. These findings suggest that tazarotene plus a mid-potency topical corticosteroid is a valuable first-line treatment option for stable plaque psoriasis.

Authors+Show Affiliations

Department of Dermatology, Centre Hospitalier Universitaire de Québec, Canada.

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

9951595

Citation

Poulin, Y P.. "Tazarotene 0.1% Gel in Combination With Mometasone Furoate Cream in Plaque Psoriasis: a Photographic Tracking Study." Cutis, vol. 63, no. 1, 1999, pp. 41-8.
Poulin YP. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis. 1999;63(1):41-8.
Poulin, Y. P. (1999). Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis, 63(1), 41-8.
Poulin YP. Tazarotene 0.1% Gel in Combination With Mometasone Furoate Cream in Plaque Psoriasis: a Photographic Tracking Study. Cutis. 1999;63(1):41-8. PubMed PMID: 9951595.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. A1 - Poulin,Y P, PY - 1999/2/10/pubmed PY - 1999/2/10/medline PY - 1999/2/10/entrez SP - 41 EP - 8 JF - Cutis JO - Cutis VL - 63 IS - 1 N2 - A photographic tracking study was performed to facilitate a visual evaluation of the effect of treating psoriatic lesions in a clinical setting with tazarotene 0.05% gel, tazarotene 0.1% gel, tazarotene 0.1% gel plus mometasone furoate as needed for irritation, or tazarotene 0.1% gel plus mometasone furoate. Tazarotene was administered once daily in the evening, and mometasone furoate was administered once daily in the morning, for 12 weeks or until clearance if this occurred first. A total of twenty patients were enrolled in this open-label study. Rates of treatment success (50% or greater improvement in psoriasis) were higher with tazarotene 0.1% monotherapy compared with tazarotene 0.05% monotherapy, and were higher still when tazarotene was used in combination with mometasone furoate. Concurrent use of this steroid also enhanced speed of efficacy, patient satisfaction, and tolerability. Furthermore, long periods of remission were achieved in patients treated with combination tazarotene plus corticosteroid therapy. These findings suggest that tazarotene plus a mid-potency topical corticosteroid is a valuable first-line treatment option for stable plaque psoriasis. SN - 0011-4162 UR - https://www.unboundmedicine.com/medline/citation/9951595/Tazarotene_0_1_gel_in_combination_with_mometasone_furoate_cream_in_plaque_psoriasis:_a_photographic_tracking_study_ DB - PRIME DP - Unbound Medicine ER -